Autonomix Medical, Inc. announced on April 30, 2025, positive outcomes from the initial phase of its first-in-human proof-of-concept trial (PoC 1) for severe pancreatic cancer pain. The study, which enrolled 20 patients, successfully met all its objectives, demonstrating statistically significant pain relief as early as 24 hours post-procedure.
Responding patients experienced a mean pain reduction of 4.16 on the Visual Analog Scale (VAS) at 7 days, representing a 53.3% improvement, and a mean reduction of 4.67 at 4-6 weeks, a 59.2% improvement. Critically, 100% of responders achieved zero opioid use at 7 days post-procedure, with 73% remaining opioid-free at 4-6 weeks, alongside an improved quality of life.
Building on these results, Autonomix has initiated a follow-on PoC 2 phase, a market expansion study that will evaluate pain management for additional visceral cancers, including gall bladder, liver, and bile duct, as well as earlier-stage pancreatic cancer patients. This strategic expansion has the potential to double the addressable market beyond pancreatic cancer pain, leveraging the platform's applicability across related conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.